Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time

Manufacturing Inspection Delays Could Impact Decision Due 27 March

 
• By Mandy Jackson
  
business financial ideas concept with coins stack and alarmclock isolate background with free copyspace for your creativity ideas text
Celgene shareholders get a payout from BMS if ide-cel and two other drugs are approved by specific deadlines • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip